Q4FY17 Results: Sun Pharmaceuticals Ltd

Sun Pharmaceuticals Ltd, the fifth largest speciality generic pharma company, reported its results for the quarter ended March 31, 2017 today. The results missed street estimates.

The company's total sales for Q3FY17 came in at Rs 7137 crore, which represents a 9.94 per cent sequential decline and 6.76 per cent YoY decline.

Its operating profit (EBIT) for the quarter was Rs 1209.4 crore and its EBIT margin stood at 16.95 per cent.

The company reported PAT of Rs 1223.7 crore, which represents a sequential QoQ decline of 16.86 per cent and a YoY decline of 13.59 per cent.

The stock of Sun Pharma remained a top loser in the Nifty50 in an otherwise positive index. The stock declined 3.9% and closed at Rs 568.55 on the BSE ahead of the results. The stock posted an intra-day high and low at Rs 598.45 and Rs 564.90, respectively.

Sun Pharma is a speciality pharma company. The company's brands are mainly prescribed for chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology, ophthalmology, orthopedics, etc. The company has only one operating segment of pharmaceuticals.